Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning

被引:12
|
作者
Jawien, Wojciech [1 ]
Wilimowska, Jolanta [2 ]
Klys, Malgorzata [3 ]
Piekoszewski, Wojciech [4 ,5 ]
机构
[1] Jagiellonian Univ, Dept Pharmaceut Biophys, Krakow, Poland
[2] Univ Hosp Krakow, Dept Diagnost, Krakow, Poland
[3] Jagiellonian Univ, Chair & Dept Forens Med, Krakow, Poland
[4] Jagiellonian Univ, Dept Analyt Chem, Fac Chem, Krakow, Poland
[5] Far Eastern Fed Univ, Sch Biomed, Vladivostok, Russia
关键词
Valproic acid; Population pharmacokinetics; Acute poisoning; Metabolic pathway; Monolix; ACTIVATED-CHARCOAL; EPILEPTIC PATIENTS; TOXICITY; HEMOPERFUSION; DISPOSITION; MANAGEMENT; CLEARANCE; DRUG;
D O I
10.1016/j.pharep.2016.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Valproic acid (VPA) is a first-line antiepileptic drug. It is used in the treatment of many different types of partial and generalized epileptic seizures. Though the clinical pharmacokinetics of VPA has been well defined, information about pharmacokinetics after overdoses is rare. The aim of this study was to try to build a population pharmacokinetic model that would describe the time course of VPA and its selected metabolites when the drug is ingested in an overdose situation. Methods: Blood samples were collected during admission to the hospital and several times during treatment for poisoning (10 men and 10 women). The concentration of VPA and its metabolites were determined by liquid chromatography coupled with mass spectrometry. For population pharmacokinetic evaluation of VPA and its metabolites, the two-compartment-model was applied. Results: The estimated doses of VPA taken ranged from 6 to 65 g, while the time after ingestion ranged from 1 to 30 h. Results showed that the beta-oxidation process exhibited Michaelis-Menten kinetics becoming saturated during acute intoxication. The same could not be said for the desaturation route. VPA therapy increased the Vmax for beta-oxidation by 59% while decontamination appeared to be of moderate efficacy lowering the F value by 34% on the average. Conclusions: None of the models perfectly described the experimental data. Important factors like the variable degree of protein binding by VPA could not be included in the models. The small number of subjects used in the study made the analysis of more covariates impossible. (C) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:340 / 349
页数:10
相关论文
共 50 条
  • [1] Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning
    Wojciech Jawień
    Jolanta Wilimowska
    Małgorzata Kłys
    Wojciech Piekoszewski
    Pharmacological Reports, 2017, 69 : 340 - 349
  • [2] VALPROIC ACID (VPA) POISONING TREATED BY HEMODIALYSIS
    BRENT, J
    YANOVER, M
    KULIG, K
    RUMACK, BH
    VETERINARY AND HUMAN TOXICOLOGY, 1988, 30 (04) : 353 - 353
  • [3] PHARMACOKINETIC STUDY OF VALPROIC ACID (VPA) IN NEONATES WITH CONVULSIONS
    HANEDA, S
    TAKEBE, Y
    KOIDE, N
    BRAIN & DEVELOPMENT, 1983, 5 (02): : 197 - 197
  • [4] ACUTE VALPROIC ACID OVERDOSE - CLINICAL COURSE AND PHARMACOKINETIC DISPOSITION OF VALPROIC ACID AND METABOLITES
    DUPUIS, RE
    LICHTMAN, SN
    POLLACK, GM
    DRUG SAFETY, 1990, 5 (01) : 65 - 71
  • [5] VALPROIC ACID (VPA) AND ITS 2-EN-METABOLITE (2-EN-VPA) - COMBINATION OF INVITRO TERATOGENESIS WITH PHARMACOKINETIC STUDIES
    LEWANDOWSKI, C
    KLUG, S
    NAU, H
    TERATOLOGY, 1986, 33 (02) : A24 - A24
  • [6] The influence of Valproic acid (VPA) and its metabolites on behavior and cognitive performance in children suffering from generalized epilepsy
    Schmidt, A
    Darius, J
    Brosz, M
    Roth, N
    Meyer, FP
    JOURNAL OF PSYCHOPHYSIOLOGY, 1995, 9 (04) : 373 - 373
  • [7] Extracorporeal elimination in acute valproic acid poisoning
    Thanacoody, Ruben H. K.
    CLINICAL TOXICOLOGY, 2009, 47 (07) : 609 - 616
  • [8] A case of hyperammonennia with acute valproic acid overdose in a VPA-naive patient
    DeMott, M. C.
    Schwarz, K. A.
    Shah, N.
    Clark, R. F.
    CLINICAL TOXICOLOGY, 2007, 45 (06): : 615 - 615
  • [9] Carbapenems as Antidotes for the Management of Acute Valproic Acid Poisoning
    Vukcevic, Natasa Perkovic
    Jovin, Vesna Mijatovic
    Ercegovic, Gordana Vukovic
    Antunovic, Marko
    Kelecevic, Igor
    Zivanovic, Dejan
    Vucinic, Slavica
    PHARMACEUTICALS, 2024, 17 (02)
  • [10] Levocarnitine for acute valproic acid poisoning: our experience
    Tincu, Radu
    Cobilinschi, Cristian
    Tincu, Iulia
    Macovei, Radu
    CLINICAL TOXICOLOGY, 2020, 58 (06) : 555 - 555